⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18301672 | 0.86 | — | — | |
| SCHEMBL9397043 | 0.65 | — | — | |
| SCHEMBL6789444 | 0.64 | — | — | |
| SCHEMBL31203126 | 0.62 | — | — | |
| SCHEMBL9719685 | 0.62 | — | — | |
| SCHEMBL4480303 | 0.61 | — | — | |
| SCHEMBL18134202 | 0.58 | — | — | |
| SCHEMBL109050 | 0.58 | EPHX1 (0.35) | — | |
| SCHEMBL187063 | 0.58 | — | — | |
| SCHEMBL11799796 | 0.58 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236611-A1 | PYRAZOLE COMPOUNDS AND USES THEREOF | ALCON INC. (CH) | 2025-07-24 | — | — | US | disclosed |
| EP-4412994-A1 | JANUS KINASE INHIBITING PYRAZOLE COMPOUNDS AND USES THEREOF | Aerie Pharmaceuticals, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| CN-118159528-A | Pyrazole compounds that inhibit Janus kinase and uses thereof | 爱瑞制药公司 | 2024-06-07 | — | — | CN | disclosed |
| WO-2023060202-A1 | JANUS KINASE INHIBITING PYRAZOLE COMPOUNDS AND USES THEREOF | AERIE PHARMACEUTICALS, INC. (US) | 2023-04-13 | — | — | WO | disclosed |
| EP-3390387-B1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma AG (DE) | 2021-11-17 | — | — | EP | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-10894784-B2 | Heteroarylbenzimidazole compounds | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-01-19 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| US-20190047980-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-02-14 | — | — | US | disclosed |
| EP-3390387-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-10-24 | — | — | EP | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
| WO-2017102091-A1 | HETEROARYLBENZIMIDAZOLE COMPOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-06-22 | — | — | WO | disclosed |
| US-7494987-B2 | Agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2009-02-24 | — | — | US | disclosed |
| US-20060040985-A1 | Therapeutic agent for treating respiratory diseases containing 4-hydroxypiperidine derivative as active ingredient | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2006-02-23 | — | — | US | disclosed |
| EP-1568688-A1 | THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2005-08-31 | — | — | EP | disclosed |
| EP-0549418-A2 | Unsaturated amides with pesticidal activity | ROUSSEL UCLAF (FR) | 1993-06-30 | — | — | EP | disclosed |